Home » Stocks » SELB

Selecta Biosciences, Inc. (SELB)

Stock Price: $3.21 USD -0.03 (-0.77%)
Updated December 4, 3:59 PM EST - Market closed

SELB Stock Price Chart

Key Info

Market Cap 346.24M
Revenue (ttm) 11.30M
Net Income (ttm) -68.32M
Shares Out 105.33M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $3.21
Previous Close $3.23
Change ($) -0.03
Change (%) -0.77%
Day's Open 3.25
Day's Range 3.18 - 3.30
Day's Volume 1,415,446
52-Week Range 1.46 - 4.52

SELB Stock News

PRNewsWire - 1 week ago

SHENYANG, China, Nov. 23, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company, 3SBio Inc.(01530.HK, the "Company"), announced today that Selecta Biosciences, Inc. (Nasdaq: SELB), th...

Zacks Investment Research - 2 weeks ago

The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Diseas...

Seeking Alpha - 3 weeks ago

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 weeks ago

Selecta (SELB) beat estimates for both earnings and revenues in the third quarter of 2020.

GlobeNewsWire - 4 weeks ago

WATERTOWN, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc.  (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogen...

GlobeNewsWire - 1 month ago

WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapi...

Zacks Investment Research - 1 month ago

In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.

The Motley Fool - 1 month ago

"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.

Other stocks mentioned: APTX, VBIV
InvestorPlace - 1 month ago

Selecta Biosciences (SELB) news for Monday includes insider buying from a Board of Directors member sending SELB stock higher. The post Selecta Biosciences News: SELB Stock Shoots 9% Higher on...

Benzinga - 1 month ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: TACO, FAF, TBK
Zacks Investment Research - 1 month ago

The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.

CNBC Television - 1 month ago

These are the stocks seeing the most insider buying this week

In his weekly exclusive for Worldwide Exchange, Brian Sullivan highlights three stocks seeing the most insider buying this week, including some biotech names.

Other stocks mentioned: GOSS, MDT
Benzinga - 1 month ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: ESI, AVO, CCXX, IMNM, LUNG
GlobeNewsWire - 1 month ago

Application of ImmTOR™  plus IGAN’s IgA p rotease to target immunoglobulin A ( IgA ) deposition, the critical event leading to IgA N ephropathy ( IgAN )

Seeking Alpha - 2 months ago

With a market cap of $171 million (10/1/2020), Selecta Biosciences is a well positioned clinical-stage biotech company, focusing on immunogenicity.

Benzinga - 2 months ago

Shares of Horizon Therapeutics PLC (NASDAQ: HZNP), which focuses on rare and rheumatic diseases, surged higher Thursday despite an absence of announcements from the biopharma. What Happened: H...

Other stocks mentioned: HZNP
The Motley Fool - 2 months ago

Disappointing phase 2 data casts doubt on SEL-212's future.

PRNewsWire - 2 months ago

STOCKHOLM and WATERTOWN, Mass., Sept. 30, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced topline data...

GlobeNewsWire - 2 months ago

All data consistent with stronger performance of SEL-212 versus pegloticase

GlobeNewsWire - 2 months ago

WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic ther...

PRNewsWire - 2 months ago

STOCKHOLM and WATERTOWN, Mass., Sept. 23, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commenceme...

GlobeNewsWire - 2 months ago

STOCKHOLM, Sweden and WATERTOWN, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced ...

GlobeNewsWire - 3 months ago

WATERTOWN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic ther...

Seeking Alpha - 3 months ago

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -153.13% and -100.00%, respectively, for the quarter ended June 2020.

Zacks Investment Research - 3 months ago

Selecta Biosciences (SELB) miss estimates for earnings and revenues in the second quarter of 2020.

GlobeNewsWire - 3 months ago

WATERTOWN, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic thera...

Zacks Investment Research - 4 months ago

In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.

GlobeNewsWire - 4 months ago

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic thera...

GlobeNewsWire - 4 months ago

WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic thera...

GlobeNewsWire - 4 months ago

STOCKHOLM, Sweden and WATERTOWN, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI ) today announced that the strategic licensing agreement with ...

Zacks Investment Research - 4 months ago

Is (SELB) Outperforming Other Medical Stocks This Year?

The Motley Fool - 4 months ago

These two healthcare stocks are risky, but they have much better chances of success than penny stocks.

Other stocks mentioned: MESO
Seeking Alpha - 5 months ago

Partnership strategy for ImmTOR platform continues to pay off with Sarepta deal immediately following $100 million upfront Sobi deal.

Zacks Investment Research - 5 months ago

Selecta Biosciences (SELB) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

The Motley Fool - 5 months ago

A bullish article is sending shares higher.

24/7 Wall Street - 5 months ago

Selecta Biosciences Inc. (NASDAQ: SELB) and Sarepta Therapeutics Inc. (NASDAQ: SRPT) have announced that they had entered into a research license and option agreement.

Other stocks mentioned: SRPT
GlobeNewsWire - 5 months ago

Application of ImmTOR plus Sarepta’s investigational gene therapies will be evaluated for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophies Application of ImmTOR plus Sarepta’s ...

Seeking Alpha - 5 months ago

It's Time To Invest In Selecta Biosciences As They Ink Massive $100 Million Upfront Deal

Seeking Alpha - 5 months ago

Selecta Biosciences Is A Buy After Major Deal

Zacks Investment Research - 5 months ago

Is (SELB) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 5 months ago

WATERTOWN, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic thera...

The Motley Fool - 5 months ago

A licensing deal for a late-stage asset failed to impress Wall Street. One analyst went as far as downgrading the biopharma stock.

PRNewsWire - 5 months ago

STOCKHOLM, and WATERTOWN, Mass., June 11, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced that the compa...

GlobeNewsWire - 5 months ago

- Strategic licensing agreement for SEL-212, a unique phase 3-ready therapy powered by Selecta’s breakthrough immune tolerance platform, ImmTOR™, with the potential to fulfil a significant unm...

Zacks Investment Research - 6 months ago

Selecta (SELB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 6 months ago

WATERTOWN, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therap...

Seeking Alpha - 6 months ago

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q1 2020 Results - Earnings Call Transcript

InvestorPlace - 7 months ago

There could be a reason penny stocks trade for under $5, but the returns can be monstrous if there's even minor share price appreciation.

Other stocks mentioned: EVRI, GERN, MNLO, ORBC, PLUG, RMTI
Seeking Alpha - 8 months ago

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q4 2019 Results - Earnings Call Transcript

About SELB

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that has completed Phase II clinical trials for the treatment of chronic refractory gout. It also engages in the development of gene therapy product candidates that are in prec... [Read more...]

Industry
Biotechnology
IPO Date
Jun 22, 2016
CEO
Carsten Brunn
Employees
39
Stock Exchange
NASDAQ
Ticker Symbol
SELB
Full Company Profile

Financial Performance

In 2019, SELB's revenue was $6.68 million, an increase of 639.42% compared to the previous year's $903,000. Losses were -$55.35 million, -15.28% less than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for SELB stock is "Buy." The 12-month stock price forecast is 6.71, which is an increase of 109.36% from the latest price.

Price Target
$6.71
(109.36% upside)
Analyst Consensus: Buy